Nuclease Market Size, Share, Growth, and Industry Analysis by Type (DNases and RNases) By Application (Academic & Research Institutes, Biopharmaceutical, and Hospitals & Diagnostic Centers), Regional Forecast To 2031

Nuclease Market Report Overview

• 
•  Request a Free Sample to learn more about this report

The global nuclease market size was USD 482.6 million in 2021 and is projected to touch USD 1011.76 million by 2031, at a CAGR of 7.7% during the forecast period.

A nuclease, which is also known as nucleodepolymerase or polynucleotidase is an enzyme that cleaves the phosphodiester bonds between nucleotides in nucleic acids. Nucleases cause single and double stranded breaks in their target molecules in various ways. They are essential machinery in living organisms for many aspects of DNA repair. Certain nuclease defects can result in genetic instability or immunodeficiency. In molecular cloning, nucleases are also widely used.

Nucleases are enzymes that break down nucleic acids such as DNA or RNA. RNases degrade RNA while DNases degrade DNA. Because nucleic acids are polymers of nucleotides, the cleavage products of DNA and RNA nuclease are similar. The primary structure of nucleases is generally poorly conserved and only minimally conserved at active sites, the surfaces of which are primarily composed of acidic and basic amino acid residues. Nucleases are divided into folding families.

COVID-19 Impact: Uptick in Gene Editing Tools Positively Influenced Market Growth

The COVID-19 emergency has benefited the global nuclease market. Even though there was shutdown of various industries and other places due to worldwide lockdown, in some applicable ways they have positively impacted and benefited the growth of the market even during The COVID-19 crisis. Nucleases play a major role in gene editing and technologies. Gene editing tools, in addition to plant improvement and disease treatments, have been used to combat COVID-19. Researchers from Georgia Institute of Technology and Emory University created gene-edited enzymes that attack the virus's polymerase chains, preventing it from producing more RNA to replicate itself and allowing the patient to recover. This new treatment will also be delivered to the lungs via nebulizer for greater accessibility and ease of administration by the patient.

Latest Trends

"Nanotechnology-Based Nucleic Acid Therapeutics Delivery Vehicles to Drive Market Growth"

Nucleases found in serum or tissue have the ability to degrade naked nucleic acid therapeutics. Nanotechnology has provided some solutions to these issues. Nanovehicles can transport nucleic acid through blood, protect the cargo from nucleases, opsonization, and glomerular filtration, induce endocytosis of the vehicle and its cargo, and finally escape from endosomes and lysosomes to release nucleic acid into the cytoplasm. To date, many nanovehicles for nucleic acid delivery have been introduced, which can be divided into two categories: viral and nonviral delivery systems.

Nuclease Market Segmentation

• 
•  Request a Free Sample to learn more about this report

• By Type

Based on type, the market share is bifurcated into DNases and RNases. The DNases segment is projected to dominate the market share during 2031.

• By Application

The market share is divided into Academic & Research Institutes, Biopharmaceutical, and Hospitals & Diagnostic Centers in terms of application. It is estimated that the biopharmaceutical segment will capture the maximum market share through 2031.

Driving Factors

"Nucleases for Cancer Diagnosis to Drive the Market Growth"

Nucleases, which are enzymes that can cleave nucleic acids, have long been thought to be potential cancer biomarkers. The implications of nucleases for biological functions, their presence in various cellular counterparts, and catalytic activity sparked interest in investigating the role of nucleases as promising cancer biomarkers. However, the most important property of these proteins, their enzymatic activity, has not been fully exploited.

Nucleases are expressed and enzymatically active both inside and outside the cell. The abundance of nucleases, combined with their catalytic enzymatic activity, transforms them into diagnostic targets that can be exploited on a molecular as well as functional level by incorporating nucleases into the appropriate detection system, thereby driving the global nuclease market growth.

"Rise in Gene Therapy to Drive the Market Growth"

The rise in the usage of gene therapy or genome therapy are another factor driving the market growth. The liver diseases which are metabolically-inherited can be treated via nuclease-mediated gene therapies. IMDs (Inherited Metabolic Diseases) of the liver are a large and diverse group of rare genetic diseases characterised by the loss or dysfunction of enzymes or proteins required for metabolic pathways in the liver. In pre-clinical studies, conventional gene therapy involving adeno-associated virus (AAV) serotype 8 vectors provided therapeutically high levels of hepatic transgene expression, facilitating disease phenotypic correction, and is currently being evaluated in clinical trials for multiple IMDs. Genome editing tools are programmable nucleases with unprecedented potential to advance the goals of IMD gene therapy.

Restraining Factors

"Complexities of Zinc Finger Nuclease Technology to Restrain Market Growth"

There are various complications found in association with zinc finger nucleases. Zinc finger nucleases (ZFNs) have been successfully used to generate genome-specific double-strand breaks, increasing gene targeting by thousands of folds. ZFNs are chimeric proteins that combine a specific DNA-binding domain with a non-specific DNA-cleavage domain. The designed zinc-finger domain's binding specificity directs the ZFN to a specific genomic site. When compared to other programmable nucleases, the use of ZFNs is frequently constrained by low targeting density and relatively high levels of off-target effects, which result in cytotoxicity.

Off-target cleavage may occur if the zinc finger domains are not specific enough for their target site or do not target a unique site within the genome of interest.

Nuclease Market Regional Insights

• 
•  Request a Free Sample to learn more about this report

"North America to Lead the Market Owing to Presence of Several Key Market Players"

In 2021, North America held the largest volume share of the global nuclease market. The region's high consumption of enzymes is primarily attributed to an increase in demand for nucleases market, mainly focused in the U.S. Apart from this most of the giant market players are particularly focused in this region as well which is a major reason for the U.S. hold in the global nuclease market share.

Key Industry Players

"Leading Players Adopt Acquisition Strategies to Stay Competitive "

Several players in the market are using acquisition strategies to build their business portfolios and strengthen their market position. In addition, partnerships and collaborations are among the common strategies adopted by companies. Key market players are making R&D investments to bring advanced technologies and solutions to the global nuclease market.

LIST OF TOP Nuclease COMPANIES

• New England Biolabs (U.S.)
• MercK (U.S.)
• Illumina (U.S.)
• Thermo Fisher Scientific (U.S.)
• Agilent Technologies (U.S.)
• Cytiva (U.S.)
• Roche (Switzerland)
• Takara Bio (Japan)
• C-LEcta (Germany)
• Aldevron (U.S.)
• Lucigen (U.S.)
• Promega Corporation (U.S.)
• Qiagen (Germany)
• Amicogen (South Korea)
• Codexis (U.S.)
• BBI Solution (U.K.)

REPORT COVERAGE

In the report, factors affecting the market from both demand and supply are evaluated and market dynamics during the forecast period are also forecasted. Also included in the report is a comprehensive PEST analysis of countries, which assesses the governmental, financial, and shared factors influencing their markets. Apart from all of these, the report also provides drivers, restraints, opportunities, and future trends.